These results validated that targeting EGFR of SAS-tumor cells and effective intracellular and mitochondrial delivery are key prerequisites for lipid nanoparticles, such as LPN-KL and SLN-KL, to display a superior antitumor efficacy and excellent hypolipidemic and hypoglycemic effects in vivo. Here, EGFR is linked to neoplasm.